Table 4.

Pharmacotherapy at Baseline and Final Visit

No Functional Improvement, N=13Functional Improvement, N=25P Value
Baseline
 ACEi, n (%)9 (69%)15 (60%)0.73
 ACEi dose, mg of lisinopril12.5±6.118.0±10.70.17
 ARB, n (%)3 (23%)7 (28%)1.00
 ARB dose, mg of losartan66.7±28.966.1±34.40.98
 β-blockers, n (%)12 (92%)23 (92%)1.00
 β-blockers dose, mg of carvedilol26.0±13.538.9±25.50.06
 Loop diuretics, n (%)4 (31%)12 (48%)0.49
 Loop diuretics dose, mg of furosemide32.5±22.240.0±28.20.60
 Calcium blockers, n (%)1 (8%)3 (12%)1.00
 Calcium blockers dose, mg of amlodipine5.0±0.08.3±2.90.42
 Aldosterone antagonist, n (%)4 (31%)5 (20%)0.69
 Aldosterone antagonist dose, mg of spironolactone25.0±0.032.5±24.40.56
 Hydralazine, n (%)0 (0%)5 (20%)0.14
 Hydralazine dose, mg98.0±71.2NA
 Nitrate, n (%)1 (8%)5 (20%)0.64
 Nitrate dose, mg120.0±038.0±31.10.07
Final visit
 ACEi or ARB, n (%)13 (100%)22 (88%)0.50
 ACEi dose, mg of lisinopril22.0±13.424.3±12.90.66
 ARB dose, mg of losartan100±091.1±58.10.80
 β-blockers, n (%)13 (100%)25 (100%)1.00
 β-blockers dose, mg of carvedilol26.9±12.339.3±23.40.09
 Loop diuretics, n (%)8 (62%)15 (60%)1.00
 Loop diuretics dose, mg of furosemide30.0±26.847.7±30.00.24
 Calcium blockers, n (%)1 (8%)5 (20%)0.64
 Calcium blockers dose, mg of amlodipine5.0±08.0±2.7NA
 Aldosterone antagonist, n (%)7 (54%)7 (28%)0.16
 Aldosterone dose, mg21.4±6.126.8±22.20.55
 Hydralazine, n (%)5 (39%)11 (44%)1.00
 Hydralazine dose, mg36.0±13.498.2±100.40.07
 Nitrate, n (%)5 (39%)14 (56%)0.50
 Nitrate dose, mg60.0±43.042.1±21.50.42
  • ACEi indicates angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blockers; and NA, not applicable.